We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Consensus Guidelines for Thyroid Cancer Molecular Tests Revised

By LabMedica International staff writers
Posted on 20 Jul 2015
Print article
Image: Histopathology of a psammoma body seen in thyroid gland papillary carcinoma (Photo courtesy of The Armed Forces Institute of Pathology).
Image: Histopathology of a psammoma body seen in thyroid gland papillary carcinoma (Photo courtesy of The Armed Forces Institute of Pathology).
National guidelines for thyroid cancer testing have been revised to reflect newly available tests that better incorporate personalized medicine into diagnosing the condition.

The specific utility of these novel, clinically available molecular tests is becoming widely appreciated, especially in perioperative decision making by the surgeon regarding the need for surgery and the extent of initial resection.

Scientists at the University of Pittsburgh Schools of the Health Sciences (PA, USA) led a panel of experts in revising national guidelines for thyroid cancer testing to reflect newly available tests that better integrate tailored personal treatment in differentiating thyroid diseases. Standardized interpretation of fine-needle aspiration (FNA) cytology for thyroid nodules has improved since the advent of a tiered Bethesda classification scheme. While concordance among cytopathologists is high (90%) for benign and malignant cytologic diagnoses, there is significant intra- and inter-observer variability for any type of indeterminate cytologic diagnosis.

The gene expression classifier (GEC) and seven-gene molecular panel (7-gene MT) are the two widely available tests at the present time. The Afirma GEC (Veracyte; South San Francisco, CA, USA) was developed as a proprietary method for molecular analysis of thyroid FNA specimens diagnosed as atypia of uncertain significance/follicular lesion of undetermined significance (AUS/FLUS) and follicular neoplasm/suspicious for follicular neoplasm (FN), with the intent of predicting benign pathology and thus avoiding unnecessary thyroidectomy for asymptomatic nodules. With an initially reported high negative predictive value, GEC combines an assay signature of 167 genes with commercial cytologic examination. A low-cost 7-gene MT test called ThyroSeq (CBLPATH; Rye Brook, NY, USA) allows pathologists to simultaneously test for multiple genetic markers of thyroid cancer using just a few cells collected from the nodule.

Other available tests use different technology to serve as accurate “rule-out” tools, but do not have the high sensitivity needed to also reliably “rule-in” cancer. In some cases, the accuracy of the “rule-out” tests depends on the prevalence of cancer in the patients seen by each individual cancer institute. This is critical because clinicians must know this rate at their institution to correctly calculate the accuracy of “rule-out” test results for each patient. The study was published online on May 18, 2015, in the journal Thyroid.

Related Links:

University of Pittsburgh Schools of the Health Sciences
Veracyte 
CBLPATH


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.